How and when do you incorporate PTEN testing in a patient newly diagnosed with metastatic hormone-sensitive prostate cancer?
Community PollStarted
How do you incorporate PTEN protein testing in a patient newly diagnosed with mHSPC?
13 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · The University of Texas Health Science Center at San Antonio
Answered on
I always incorporate PTEN testing in all patients with mHSPC (mAPMS) using NGS testing. Recently, with the approval of capivasertib, I have also started doing PTEN IHC testing. The NGS information is prognostic in how I educate the patient as well as understand their disease. It also comes as part o...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Duke University Hospital
Answered on
Based on the FDA approval of ADT/Abiraterone and Capivasertib for patients with PTEN-deficient metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) I recommend testing with an FDA-approved immunohistochemistry (IHC) test on the archival tumor tissue of patients with metastatic pr...
Join for free or sign in to see the full answer